Phase 2 Study Of Zenocutuzumab (Mcla-128), A Bispecific Her2/Her3 Antibody In Nrg1 Fusion-Positive Advanced Solid Tumors
JOURNAL OF THORACIC ONCOLOGY(2021)
关键词
NRG1 fusion, bispecific HER2/HER3 antibody, zenocutuzumab (MCLA-128)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要